Drug
Ddy391
Ddy391: highest development phase Phase 2, developed by Novartis. 3 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Novartis
Trials
| Drug | Phase | Indication |
|---|---|---|
| DDY391 NCT07801495 | Phase 2 | Moderate to Severe Psoriatic Arthritis |
| DDY391 NCT07737743 | Phase 2 | Sjögren's Disease |
| DDY391 NCT07923773 | Phase 2 | Moderate to Severe Psoriatic Arthritis |
Latest
No recent events.
Follow Ddy391 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.